- Home
- BCAB vs TRT Comparison
BCAB vs TRT Comparison
Compare BCAB & TRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- TRT
- Stock Information
- Founded
- BCAB 2007
- TRT 1958
- Country
- BCAB United States
- TRT United States
- Employees
- BCAB N/A
- TRT N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- TRT Industrial Machinery/Components
- Sector
- BCAB Health Care
- TRT Technology
- Exchange
- BCAB Nasdaq
- TRT Nasdaq
- Market Cap
- BCAB 21.6M
- TRT 22.7M
- IPO Year
- BCAB 2020
- TRT N/A
- Fundamental
- Price
- BCAB $0.45
- TRT $5.31
- Analyst Decision
- BCAB Hold
- TRT
- Analyst Count
- BCAB 3
- TRT 0
- Target Price
- BCAB $1.00
- TRT N/A
- AVG Volume (30 Days)
- BCAB 561.4K
- TRT 2.9K
- Earning Date
- BCAB 08-07-2025
- TRT 09-22-2025
- Dividend Yield
- BCAB N/A
- TRT N/A
- EPS Growth
- BCAB N/A
- TRT N/A
- EPS
- BCAB N/A
- TRT 0.00
- Revenue
- BCAB $11,000,000.00
- TRT $35,548,000.00
- Revenue This Year
- BCAB N/A
- TRT N/A
- Revenue Next Year
- BCAB N/A
- TRT N/A
- P/E Ratio
- BCAB N/A
- TRT $1,205.32
- Revenue Growth
- BCAB N/A
- TRT N/A
- 52 Week Low
- BCAB $0.24
- TRT $4.62
- 52 Week High
- BCAB $2.53
- TRT $7.88
- Technical
- Relative Strength Index (RSI)
- BCAB 65.33
- TRT 44.25
- Support Level
- BCAB $0.35
- TRT $5.21
- Resistance Level
- BCAB $0.38
- TRT $5.53
- Average True Range (ATR)
- BCAB 0.03
- TRT 0.10
- MACD
- BCAB 0.01
- TRT -0.04
- Stochastic Oscillator
- BCAB 90.66
- TRT 17.38
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About TRT Trio-Tech International
Trio-Tech International is a provider of third-party semiconductor testing and burn-in services through its laboratories in Southeast Asia. The company operates in four segments namely Manufacturing, Testing services, Distribution, and Real Estate. Its Manufacturing segment manufactures both front-end and back-end semiconductor test equipment and related peripherals. The Testing Services segment renders services to the manufacturer and purchaser of semiconductors and other entities. Its Distribution segment is involved in the distribution of its products. The company's Real Estate segment consists of investment in real estate. Its geographical area of operations includes the United States, Singapore, Malaysia, Thailand, and China. It derives maximum revenue from Testing services Segment.